T cell immunoreceptor with Ig and ITIM domains (TIGIT)

Overview

TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains) is an inhibitory immune checkpoint receptor expressed predominantly on T cells, natural killer cell, and regulatory T cell subsets. Structurally, TIGIT contains an extracellular immunoglobulin variable domain, a transmembrane region, and an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM), through which it transduces suppressive signals upon engagement with its principal ligand CD155 (PVR). By dampening T cell and NK cell activation downstream of CD155 signaling, TIGIT functions as a critical brake on immune responses, contributing to peripheral tolerance and the prevention of autoimmunity. Alongside canonical checkpoints such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4), the Programmed cell death 1 (PD-1), LAG3, and TIM-3, TIGIT has been classified as a key regulator of immune homeostasis whose dysregulation in pathological contexts—most notably cancer—enables immune evasion by malignant cells.

TIGIT has emerged as a prominent target in immuno-oncology, attracting substantial interest as a complement or alternative to established PD-1/PD-L1 blockade. Its immunosuppressive pathways are distinct but interconnected with those engaged by PD-1, providing a rationale for combinatorial therapeutic strategies. Beyond oncology, accumulating evidence implicates TIGIT in autoimmune and inflammatory disease contexts, as well as in the regulation of vaccine-induced adaptive immunity, broadening its relevance across the spectrum of translational immunology.

Recent Publications Summary

Recent studies have continued to position TIGIT as an immune checkpoint of interest across cancer immunotherapy and immune profiling. In breast cancer, artemisinin liposomes were investigated for their effects on metastasis and apoptosis through the TIGIT/CD155 signaling axis, with accompanying in vitro assays, mouse tumor studies, and analyses of Src, Akt, Mtor, and Stat3 signaling 42507162Jul. In renal cancer, a supramolecular multi-target peptide inhibitor was designed to combine VEGF/Tie2 targeting with TIGIT blockade, aiming to synchronize vascular normalization, effector T-cell infiltration, and checkpoint inhibition within the tumor microenvironment 41705472Feb. TIGIT was also incorporated into a tumor-targeted IL-12 fusion protein, αTIGIT-IL12, which selectively localized to tumors and engaged intratumoral natural killer and CD8+ T cells, producing strong antitumor activity in multiple mouse models with improved safety relative to wild-type IL-12 42302794Jun.

Beyond direct therapeutic targeting, TIGIT has been examined as a biomarker and immune-state marker in several disease settings. In rheumatoid arthritis and spondyloarthritis, PD-1 and TIGIT coexpression on CD4+ T cells was quantified to assess associations with disease characteristics and anti-TNF response 42161414May. In classical Hodgkin lymphoma, TIGIT expression patterns in the tumor microenvironment were evaluated in relation to clinicopathological parameters, reflecting ongoing interest in TIGIT as a marker of immune evasion in lymphoma 42049433Apr. In inborn errors of immunity, baseline transcriptional profiling before BNT162b2 vaccination identified TIGIT among genes more strongly induced in activated memory B cells and peripheral T follicular helper cells from high responders, suggesting a role in immune readiness for antibody production 42027105Apr.

Several publications also placed TIGIT in the broader landscape of cancer immunotherapy development. A review of breast cancer checkpoints highlighted TIGIT among emerging non-classical immune checkpoints that may mediate immune escape through pathways distinct from PD-1/PD-L1 42059928Apr. A global analysis of TIGIT-targeted cancer clinical trials reported 241 unique protocols, with monoclonal antibodies dominating the field and a growing emphasis on Fc-domain engineering and bispecific strategies, while also noting substantial trial termination or closure rates and a strong focus on non-small cell lung cancer 42142605May. In metastatic prevention research, Salmonella-trained natural killer cells were reported to outperform conventional PD-1 and TIGIT blockade in preventing metastasis, underscoring that TIGIT inhibition remains one comparator within a rapidly evolving immunotherapy landscape 42237539Jun.

Additional work linked TIGIT to the tumor immune microenvironment in T-cell acute lymphoblastic leukemia, where CCR4+ FOXP3+ regulatory T cells in bone marrow were found to express immune checkpoints including PD-1 and TIGIT and were discussed as potential targets in the context of anti-CCR4 therapy 41671457Feb. Together, these studies show TIGIT being explored both as a direct therapeutic target and as a marker of immune regulation across cancer, inflammatory disease, and vaccine response, with current strategies ranging from checkpoint blockade and fusion proteins to multi-target peptide systems and biomarker-based immune profiling 42507162Jul42302794Jun41705472Feb42161414May42049433Apr42027105Apr42142605May42237539Jun41671457Feb.

What Changes, What Holds

1. TIGIT is being extended from a checkpoint target into a therapeutic node in multi-mechanism antitumor design
REINFORCES These studies do not displace the established view of TIGIT as an inhibitory immune checkpoint in cancer; they sharpen it by showing that current development is increasingly built around combining TIGIT modulation with vascular, cytokine, and signaling interventions. The main implication is practical rather than conceptual: TIGIT remains a valid immuno-oncology target, but its most plausible use is now as part of integrated tumor-microenvironment strategies rather than as a stand-alone lever. 42507162Jul41705472Feb42302794Jun

2. TIGIT is emerging as a disease-state marker, but not yet as a validated clinical biomarker
NEW DIRECTION The Overview already allows TIGIT as a regulator in inflammatory disease and vaccine responses, but it does not claim biomarker utility. These reports move TIGIT into that space by linking expression patterns to treatment response, lymphoma microenvironment features, and vaccine responsiveness. That broadens its role from mechanism to readout, but the evidence remains associative and context-specific, so clinical use would still need prospective validation and standardization. 42161414May42049433Apr42027105Apr

3. TIGIT-targeted development is maturing, but the field still lacks a settled winner
REINFORCES Rather than revising the baseline, this work confirms that TIGIT sits within the established immuno-oncology pipeline and that the main question is how best to exploit it. The review-level synthesis and trial landscape reinforce the idea that TIGIT is a major checkpoint program, while also underscoring uncertainty about which formats and combinations will succeed. The comparison with other metastasis-prevention approaches does not weaken TIGIT’s relevance; it mainly shows the competitive therapeutic environment it must outperform. 42059928Apr42142605May42237539Jun

4. TIGIT is also being used to map suppressive immune niches in leukemia, extending its relevance beyond solid tumors
NEW DIRECTION The Overview already frames TIGIT as a cancer immune-evasion marker, but it does not specifically place it in T-cell acute lymphoblastic leukemia or in CCR4-directed regulatory T-cell targeting. This work broadens the disease map by tying TIGIT to a leukemia bone-marrow suppressive compartment, suggesting it may help define which immune subsets are most relevant to anti-CCR4 strategies. That is an extension of the cancer story, not a replacement for the checkpoint model. 41671457Feb

Overview update candidates: TIGIT as a biomarker/immune-state marker in specific diseases; TIGIT’s role in leukemia tumor immune microenvironments.